Fulgent Genetics (NASDAQ:FLGT) Share Price Passes Below 50 Day Moving Average – Time to Sell?

Posted by Stanley Muller on Aug 20th, 2026

Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $19.40 and traded as low as $18.96. Fulgent Genetics shares last traded at $19.74, with a volume of 264,961 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Wall Street Zen cut shares of Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Fulgent Genetics in a research note on Monday, July 6th. Finally, Piper Sandler boosted their target price on Fulgent Genetics from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $27.50.

Read Our Latest Report on Fulgent Genetics

Fulgent Genetics Stock Performance

The company’s 50 day simple moving average is $19.40 and its 200-day simple moving average is $18.36. The firm has a market capitalization of $543.05 million, a PE ratio of -7.00 and a beta of 0.90.

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. The business had revenue of $85.39 million for the quarter, compared to the consensus estimate of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. On average, equities research analysts forecast that Fulgent Genetics, Inc. will post -3.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Jian Xie sold 2,146 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $38,391.94. Following the completion of the sale, the chief operating officer owned 367,605 shares in the company, valued at $6,576,453.45. The trade was a 0.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,688 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $30,198.32. Following the completion of the sale, the insider directly owned 990,374 shares of the company’s stock, valued at approximately $17,717,790.86. This represents a 0.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 5,980 shares of company stock valued at $106,360 over the last ninety days. 36.18% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Allworth Financial LP purchased a new position in shares of Fulgent Genetics in the second quarter worth about $25,000. Farther Finance Advisors LLC lifted its stake in shares of Fulgent Genetics by 69.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after acquiring an additional 548 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in Fulgent Genetics during the 4th quarter valued at about $35,000. Legal & General Group Plc purchased a new stake in Fulgent Genetics during the 2nd quarter valued at about $38,000. Finally, Caitong International Asset Management Co. Ltd grew its position in Fulgent Genetics by 214.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock worth $48,000 after acquiring an additional 1,251 shares during the last quarter. 48.06% of the stock is owned by institutional investors.

Fulgent Genetics Company Profile

(Get Free Report)

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.